ReviewTherapeutic advances in medical oncology2018
PD-L1 expression testing in non-small cell lung cancer.
Review in Therapeutic advances in medical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 4 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Imaging-based adipose biomarkers for predicting clinical outcomes of cancer patients treated with immune checkpoint inhibitors: a systematic review.Frontiers in oncology · 2023Pooled it
- Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- Gene-Guided Treatment Decision-Making in Non-Small Cell Lung Cancer - A Systematic Review.Frontiers in oncology · 2021Pooled it
- Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.Advances in therapy · 2019Guideline
- Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.The oncologist · 2020Trial
- Relationship Between EGFR Mutation Status and Clinicopathological Parameters in Non-Small Cell Lung Carcinomas and Correlation of PD-L1 Expression.Medicina (Kaunas, Lithuania) · 2026Article
- Prognostic Value of Systemic Inflammation Markers (NLR and Haemoglobin) in Non-Small Cell Lung Cancer: Survival Analysis from a Real-World Single-Centre Cohort Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Circulating Tumor Cell PD-L1 and Peripheral Blood CD8Cancer management and research · 2026Article
- Targeting CPS1 attenuates lung cancer metastasis by regulating EMT through an epigenetic mechanism.Theranostics · 2026Article
- Immune checkpoint inhibitor-induced nephrotic syndrome: a pharmacovigilance analysis of 404 FAERS cases and literature case series.Renal failure · 2025Article
- Inflammation-Based Prognostication in Advanced-Stage NSCLC: A Retrospective Cohort Study.Cancers · 2025Article
- Assessing PD-L1 expression in non-small cell lung carcinoma: a prospective study of matched fine-needle aspirates, core biopsies, and resection specimens using alcohol and forming fixatives.The journal of pathology. Clinical research · 2025Article
- Advancements in Gene Therapy for Non-Small Cell Lung Cancer: Current Approaches and Future Prospects.Genes · 2025Review
- Comparison of PD-L1 Expression Between Preoperative Biopsy Specimens and Surgical Specimens in Non-Small Cell Lung Cancer.Cancers · 2025Article
- Unraveling the complexity of PD-L1 assays: a descriptive review of the methodology, scoring, and practical implications.Frontiers in oncology · 2025Review
- DNA Methylation in Lung Cancer: Predictive Biomarkers for Effective Immunotherapy.International journal of general medicine · 2025Review
- Multi-sequence MRI based radiomics nomogram for prediction expression of programmed death ligand 1 in thymic epithelial tumor.Frontiers in immunology · 2025Article
- Autofluorescence Virtual Staining System for H&E Histology and Multiplex Immunofluorescence Applied to Immuno-Oncology Biomarkers in Lung Cancer.Cancer research communications · 2025Article
- PD-L1 expression, tumor-infiltrating lymphocytes, and mismatch repair proteins status in digestive neuroendocrine neoplasms: exploring their potential role as theragnostic and prognostic biomarkers.Virchows Archiv : an international journal of pathology · 2024Article
- Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System.Pharmaceuticals (Basel, Switzerland) · 2024Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, immunotherapy has revolutionized and changed the standard of care in patients with advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors, fundamentally those that act by blocking the programmed cell death receptor-1 (PD-1) and its ligand the programmed cell death ligand-1 (PD-L1) have emerged as novel treatment strategies in NSCLC, demonstrating undoubted superiority over chemotherapy in terms of efficacy. Several of these immune checkpoint modulators have recently gained regulatory approval for the treatment of advanced NSCLC, such as nivolumab, atezolizumab and pembrolizumab in first-line (only the latter) and second-line settings, and more recently, durvalumab as maintenance after chemoradiotherapy in locally advanced disease. There is consensus that PD-L1 expression on tumor cells predicts responsiveness to PD-1 inhibitors in several tumor types. Hence PD-L1 expression evaluated by immunohistochemistry (IHC) is currently used as a clinical decision-making tool to support the use of checkpoint inhibitors in NSCLC patients. However, the value of PD-L1 as the 'definitive' biomarker is controversial as its testing is puzzled by multiple unsolved issues such as the use of different staining platforms and antibodies, the type of cells in which PD-L1 is assessed (tumor
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.